A recent white paper recaps the many barriers to biosimilar adoption in the United States and proposes a few ways that plans could change their reimbursement policies to help boost uptake.
A recent white paper recaps the many barriers to biosimilar adoption in the United States and proposes a few ways that plans could change their reimbursement policies to help boost uptake.
The paper, by Millman, said that fixed reimbursement, a system in which providers would be reimbursed the same amount no matter which product was administered (reference product or biosimilar) would create an incentive to prescribe the lowest-price product.
Differential reimbursement, meanwhile, would allow a larger markup on biosimilars so that providers would be safeguarded from a loss in profits. Commercial payers would pay more in markup, but since they have a lower average sales price, it would be less expensive to pay for biosimilars with a higher markup than an originator product with a lower markup. This would lead to higher biosimilar reimbursement for commercial payers but overall savings if providers had a financial incentive to prescribe biosimilars.
Federal policy changes could also increase the use of biosimilars, the paper said. Specifically, it cited the following:
The paper also cited the FDA’s Biosimilar Action Plan, including the 4 key strategies to induce competition in the US market. They include increasing efficiency around the development and approval process; expanding the Purple Book in order to increase clarity and support around biosimilar development, as well as the Biosimilar Product Development program to speed up and promote development; an education initiative; and reducing attempts to delay approval by originator manufacturers of reference products.
The report notes that some of the most “meaningful solutions are largely beyond the authority of the FDA.”
In fact, this week HHS issued a proposed rule that could help the market for biosimilars. The rule is intended to reduce patients’ out-of-pocket costs for prescription drugs by blocking rebates and discounts given to pharmacy benefit managers (PBMs), Part D plans, and Medicaid managed care organizations and encourage discounts to go straight to patients.
The rule would exclude rebates from safe harbor protections that currently shelter drug makers’ rebates from penalties under the federal anti-kickback statute, and would create new safe harbor for discounts offered to patients, as well as fixed-fee service arrangements between drug makers and PBMs.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) in New Zealand throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in 2022.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.